Anemia – defined by hemoglobin levels less than 100g/l – is common in individuals with cancer and can be induced by chemotherapy; this can lead to poor physical performance, interruptions in treatment schedules, reduced treatment response and poor prognosis. Anemia can be corrected through transfusion with packed red blood cells (RBC) or administration of iron supplementation; however, there are no standardized guidelines for treatment. Treatment with intravenous (IV) iron reduces the need for RBC transfusions and its associated adverse effects (e.g., risk of reactions and infection). An increase in serum hemoglobin levels can result in better quality of life for affected patients and may improve survival; however, the impact of iron supplementation in ovarian cancer has not been directly studied.

The objectives of this clinical trial are to:

• Examine the impact of IV iron infusion on patient outcomes in ovarian cancer, including quality of life and survival
• Operationalize treatment of anaemia in ovarian cancer patients
• Estimate the risks and benefits of iron infusion, to better inform anemia treatment decision-making for patients and physicians.